Becton Dickinson
BDX
$154.85
-0.51%
Becton, Dickinson and Co. (BD) is a global leader in the healthcare sector, specifically within the Medical - Instruments & Supplies industry, manufacturing and distributing a broad portfolio of medical surgical products, diagnostic instruments, and biopharma systems. The company is distinguished as the world's largest manufacturer in its core categories, operating as a diversified healthcare giant with a significant international footprint, deriving 43% of its revenue from outside the U.S. The current investor narrative is heavily focused on the company's post-spinoff structure and its ability to navigate a challenging market environment, with recent attention likely centered on its quarterly results and the subsequent stock price volatility, reflecting debates over growth sustainability and margin pressures in a post-pandemic landscape.…
BDX
Becton Dickinson
$154.85
Investment Opinion: Should I buy BDX Today?
Rating: Hold. The core thesis is that BDX is a fundamentally sound but currently challenged company trading at a reasonable, but not compelling, valuation, requiring evidence of operational stabilization before a more constructive view is warranted.
Supporting evidence includes a forward PE of 11.74x, which is conservative for a healthcare giant, and robust annual FCF of $2.63B supporting the 3.6% dividend yield. However, this is counterbalanced by weak momentum: revenue growth of just 1.63% YoY, a sequential decline in gross margin to 44.63%, and a stock price down 23.5% over three months. Analyst sentiment is mixed (Buy and Hold), reflecting this uncertainty, with EPS estimates of $16.91 providing a benchmark for recovery.
The thesis would upgrade to a Buy if the forward PE compressed further toward 10x alongside evidence of margin stabilization (gross margin holding above 45%) and a return to sequential revenue growth. It would downgrade to a Sell if revenue growth turns negative YoY or gross margins fall below 43%, signaling deeper problems. Relative to its own history and the challenging fundamentals, the stock appears fairly valued, not deeply undervalued, as the discount reflects real, not perceived, headwinds.
Sign up to view all
BDX 12-Month Price Forecast
BDX presents a classic 'show me' story. The valuation is undemanding, and the high dividend yield supported by strong cash flow offers downside protection. However, the burden of proof is squarely on management to demonstrate that the sequential deterioration in Q1 2026 was an anomaly, not a trend. The neutral stance reflects this balance: the risk/reward is not skewed enough to recommend buying into continued operational weakness, but selling after a 20%+ decline and into a 11.7x forward multiple seems premature. The stance would turn bullish on evidence of quarterly sequential improvement in revenue and margins; it would turn bearish on another quarter of sequential decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $201.31 and implied upside of +30.0% versus the current price.
Average Target
$201.31
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$124 - $201
Analyst target range
BDX is covered by a limited set of 6 analysts, with institutional ratings showing a mix of Buy and Hold/Neutral stances, including recent reaffirmations from firms like Argus Research (Buy) and Citigroup (Buy) alongside neutral ratings from JP Morgan and Wells Fargo. The consensus sentiment leans cautiously optimistic, but the average target price is not explicitly provided in the data; however, analyst estimates point to an average EPS forecast of $16.91 for the coming period, which, when combined with the forward PE, suggests a fundamental valuation framework that analysts are monitoring closely. The target price range is also not specified, but the wide dispersion in recent stock price action—from a high near $210 to a low near $154—reflects high uncertainty and a lack of clear directional conviction among market participants; the recent cluster of analyst actions in February 2026, following earnings, indicates the stock is under active review with the current price likely testing the lower bounds of fair value estimates.
Bulls vs Bears: BDX Investment Factors
The evidence currently tilts bearish, driven by the stock's severe technical breakdown, sequential deterioration in revenue and margins, and massive underperformance relative to the market. The bull case rests on a deep valuation discount and expectations for an earnings recovery, but these are forward-looking hopes against a backdrop of concrete negative momentum. The single most important tension in the investment debate is whether the significant compression in the forward PE ratio (11.74x) correctly anticipates a fundamental earnings rebound, or if it is merely catching down to a new reality of slower growth and persistent margin pressure. The resolution of this tension, visible in upcoming quarterly results, will determine the stock's direction.
Bullish
- Strong Forward PE Discount: The forward PE of 11.74x represents a significant discount to the trailing PE of 19.76x, implying the market is pricing in a substantial earnings recovery. This forward multiple appears conservative for a large-cap healthcare leader, suggesting potential undervaluation if earnings stabilize.
- Robust Free Cash Flow Generation: The company generates substantial annual free cash flow of $2.63 billion (TTM), providing a solid foundation for shareholder returns and strategic flexibility. This strong cash flow supports the current dividend yield of 3.6% and a high payout ratio of 71.3%.
- Defensive Low Beta Profile: BDX's beta of 0.352 indicates it has been significantly less volatile than the broader market, a defensive trait that may appeal to risk-averse investors. This low correlation was evident as the stock fell 20.2% over the past year while the S&P 500 rose 34.9%.
- Analyst EPS Growth Expectations: Analysts forecast average EPS of $16.91 for the coming period, which, if achieved, would represent a significant increase from recent quarterly EPS figures. This forward estimate underpins the discounted forward PE and suggests confidence in a profitability rebound.
Bearish
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 20.2% over the past year and 23.5% over the last three months. It trades at just 84.6% of its 52-week high, having broken down sharply from the $210 level to the $150s, indicating persistent selling pressure.
- Sequential Revenue & Margin Pressure: Q1 2026 revenue of $5.25B grew only 1.63% YoY and declined sequentially from $5.89B in Q4 2025. Gross margin compressed to 44.63% from 47.5% in the prior quarter, signaling potential top-line weakness and cost inflation headwinds.
- Weak Profitability Metrics: Net margin for the latest quarter was 7.27%, down from 8.37% in Q4 2025. Return on Equity (6.61%) and Return on Assets (4.08%) are moderate at best, indicating suboptimal efficiency in generating profits from its substantial capital base.
- High Short Interest: A short ratio of 3.92 suggests significant bearish sentiment and speculative positioning against the stock. This high level of short interest can act as a headwind for any recovery attempt and reflects deep skepticism about near-term prospects.
BDX Technical Analysis
The prevailing price trend for BDX is a pronounced downtrend, characterized by a 1-year price change of -20.22% and a 6-month decline of -16.16%. The stock is currently trading at $158.54, which is approximately 84.6% of its 52-week high of $187.35, indicating it has retreated significantly from its peak but remains well above its 52-week low of $127.59; this positioning suggests the stock is in a corrective phase rather than a deep value opportunity, having given up a substantial portion of its prior gains. Recent momentum has been sharply negative, with the stock down 23.45% over the last three months and showing only a marginal 0.29% gain over the past month, signaling that the severe selling pressure may be abating but a clear recovery trend has not yet been established, creating a divergence from the longer-term downtrend that could indicate a potential basing or consolidation phase. Key technical support lies near the 52-week low of $127.59, while immediate resistance is at the recent breakdown level around $171.68 (the price on 2026-02-10); a sustained break below support would signal a continuation of the bearish trend, whereas a reclaim of the $180-$190 zone would be necessary to suggest a reversal, with the stock's low beta of 0.352 indicating it has been significantly less volatile than the broader market (SPY) during this decline, which may appeal to defensive investors but also suggests limited momentum-driven upside potential.
Beta
0.35
0.35x market volatility
Max Drawdown
-33.5%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-23.5%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +8.5% |
| 3m | -23.3% | +2.8% |
| 6m | -16.7% | +4.6% |
| 1y | -23.5% | +32.3% |
| ytd | -20.6% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory shows modest growth but with signs of sequential deceleration; for the quarter ending December 31, 2025, revenue was $5.252 billion, representing a year-over-year growth of 1.63%, however, this marks a decline from the prior quarter's revenue of $5.89 billion (Q4 2025) and $5.509 billion (Q3 2025), indicating potential top-line pressure or seasonality. The company remains profitable, with net income of $382 million for the latest quarter and a net margin of 7.27%, though profitability has weakened from the $493 million net income in the prior quarter; gross margin for Q1 2026 was 44.63%, which is down from 47.5% in Q4 2025, suggesting margin compression that could be due to product mix or cost inflation. The balance sheet and cash flow position appear stable, with a debt-to-equity ratio of 0.755, a current ratio of 1.113, and robust annual free cash flow generation of $2.631 billion (TTM); the company's return on equity of 6.61% and return on assets of 4.08% indicate moderate but acceptable efficiency in generating profits from its capital base, supported by consistent operating cash flow which funds dividends and share repurchases.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.44%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given BDX's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 19.76x and a forward PE of 11.74x, with the significant discount in the forward multiple implying the market anticipates a substantial recovery in earnings over the next twelve months. Compared to sector averages, BDX's trailing PE of 19.76x is difficult to contextualize without a provided industry average, but its forward PE of 11.74x appears conservative for a large-cap healthcare company, suggesting the market is not pricing in a high-growth scenario and may be applying a discount due to recent operational headwinds. Historically, the stock's own trailing PE has fluctuated significantly, with a recent high of 33.5x in Q1 2025 and a low around 13.35x in Q3 2025; the current multiple of 19.76x sits roughly in the middle of this recent range, indicating the stock is neither priced for extreme optimism nor deep pessimism relative to its own recent history, potentially offering a balanced entry point if fundamentals stabilize.
PE
19.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~107x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on deteriorating profitability and growth stagnation. Net income fell from $493M in Q4 2025 to $382M in Q1 2026, a 22.5% sequential drop, while gross margin compressed 287 basis points in the same period. Revenue growth has slowed to a mere 1.63% YoY, raising concerns about the company's ability to reignite top-line expansion post-spinoff. The high dividend payout ratio of 71.3%, while supported by strong cash flow, leaves less room for error if earnings continue to decline.
Market & Competitive Risks are highlighted by valuation compression and severe underperformance. The stock's trailing PE of 19.76x sits in the middle of its recent historical range (13.35x to 33.5x), but the forward PE of 11.74x suggests the market is applying a significant discount due to operational headwinds. With a beta of 0.35, the stock has not benefited from the market's rise, indicating company-specific issues are paramount. The sharp price decline from over $210 to ~$158 following the Q1 2026 earnings release on February 9, 2026, demonstrates high sensitivity to disappointing results.
Worst-Case Scenario involves a failure to stabilize margins and revenue, leading to further earnings downgrades and multiple compression. A specific chain could be: Q2 earnings miss expectations, gross margins fall below 44%, and guidance is cut. This could trigger analyst downgrades and force the stock to re-test its 52-week low of $127.59. From the current price of $158.54, this represents a realistic downside of approximately -19.5%. A more severe scenario, factoring in the maximum drawdown of -33.6%, could see losses approach -30% if negative sentiment becomes entrenched.
FAQ
The key risks are, in order of severity: 1) Operational: Continued margin compression (gross margin fell to 44.63% in Q1) and revenue stagnation (1.63% YoY growth). 2) Technical & Sentiment: The stock is in a severe downtrend with high short interest (short ratio 3.92), which can perpetuate selling pressure. 3) Competitive/Macro: As a global company (43% int'l revenue), it is exposed to currency fluctuations and potential pricing pressure in its core medical supplies markets. 4) Execution: Failure to successfully navigate the post-spinoff environment and deliver on cost savings.
The 12-month forecast is a range of outcomes centered on a base case. The most likely scenario (60% probability) is a base case with the stock trading between $155 and $175, as operational performance stabilizes but fails to inspire multiple expansion. The bull case (25% probability) sees a rally to $187-$210 on successful execution and margin recovery. The bear case (15% probability) could see a decline toward the $128-$150 range if fundamentals worsen. The key assumption behind the base case is that the company meets the analyst EPS estimate of $16.91, justifying the current forward multiple.
BDX appears fairly valued to slightly undervalued based on forward earnings, but the discount is justified by current headwinds. The trailing PE of 19.76x is mid-range historically, but the forward PE of 11.74x is notably low, suggesting the market expects only modest growth. Compared to its own recent peak valuation (PE of 33.5x), it is cheap, but that peak reflected different expectations. The current valuation implies the market expects low-single-digit earnings growth and has little confidence in a near-term rebound, making it a fair price for the visible fundamentals.
BDX is a conditional buy, suitable primarily for patient, income-focused investors. The forward PE of 11.74x and dividend yield of 3.6% offer value and income, but the stock carries significant near-term risk as evidenced by its 23.5% decline over three months and sequential margin compression. It is a good buy for those who believe the company's operational challenges are temporary and are willing to wait for a turnaround, using the dividend as compensation. For growth-oriented or momentum investors, it is not a good buy given the weak price trend and slowing revenue growth.
BDX is suitable for a long-term investment horizon of 3-5 years, not short-term trading. Its low beta (0.35) and high dividend yield are hallmarks of a long-term holding for income and capital preservation. The current operational challenges are unlikely to be resolved in a single quarter, requiring patience. The stock's high short-term volatility, as seen in the 23% 3-month drop, makes it a poor candidate for short-term trades. A minimum holding period of 12-18 months is suggested to allow for the execution of the turnaround strategy and for the dividend to offset interim price volatility.